NTAD: A longitudinal neuroimaging dataset of Alzheimer's disease pathology

NTAD provides multi-modal longitudinal imaging and biomarker data from 70 biomarker-positive early dementia/MCI participants with Alzheimer’s disease over 2.5 years, plus 35 baseline healthy controls.

• Why it matters: There is a need to develop treatments that slow, reverse, or prevent Alzheimer’s disease, but progress depends on identifying and validating biomarkers tied to neurophysiology and treatable pathology.
• What they did: The dataset combines simultaneous magneto- and electro-encephalography, 3-Tesla structural and functional MRI, Amyloid-beta PET, and cerebrospinal fluid and blood proteomic biomarkers, with repeated AD assessments at ~3 weeks, 15 months, and 28 months.
• The result: NTAD enables discovery and validation of novel biomarkers of Alzheimer’s disease neurophysiology and supports studies linking neuroimaging measures to treatable pathology through access via DPUK in pseudonymised BIDS format.

AI summary of the abstract · may contain errors · not medical advice · read the paper.